BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly to $865 from $710 and keeps an Outperform rating on the shares after its Q4 earnings beat and guidance. Consensus estimates again underestimated tirzepatide growth as demand continues to outstrip supply, and this ongoing demand further supports BMO’s raised target price as the firm sees no signs of this stopping soon, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Gains after Strong Q4 Results
- Options Volatility and Implied Earnings Moves Today, February 06, 2024
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
- Eli Lilly sees FY24 EPS $12.20-$12.70, consensus $12.43
- Eli Lilly reports Q4 EPS $2.49, consensus $2.19